• Ertapenem Sodium Salt in Resistance Workflows

  2026-09-12

  Build a practical Ertapenem sodium salt workflow that links broth microdilution with carbapenemase detection, plasmid localization, and transfer analysis. The approach converts a broad-spectrum phenotype into evidence for antibiotic resistance research while clearly separating assay observations from clinical interpretation.

• Protease and Phosphatase Inhibitor Cocktail Workflow

  2026-09-11

  Protect protein abundance and phosphorylation states from the moment cells or tissues are disrupted. This EDTA-free, 100X formulation is especially useful for metal-sensitive signaling assays, phosphoprotein immunoblotting, organoid studies, and comparative proteomics.

• Cefoperazone Sodium Salt: Assay Logic

  2026-09-10

  Cefoperazone sodium salt is a β-lactam research tool for studying antibacterial activity, enzyme stability, and biliary tract infection models. This guide goes beyond compound description to show how comparator data, assay design, and formulation choices shape defensible experimental conclusions.

• PTT and CD47 Blockade in Oral Cancer

  2026-09-10

  A 2026 study shows that photothermal therapy (PTT) can strengthen CD47 blockade in oral squamous cell carcinoma by coupling calreticulin-dependent phagocytic signaling with extracellular matrix remodeling. The findings clarify why blocking a tumor cell “don’t eat me” signal may be insufficient without both an “eat me” cue and improved macrophage access.

• NAD+ Workflows for AMPK Energy-Stress Assays

  2026-09-09

  Build reproducible NAD+ assays that separate redox chemistry, enzyme activity, and autophagy signaling during energy stress. This workflow translates new AMPK–ULK1 findings into practical controls for metabolic, deacetylation, and inhibitor-design experiments.

• MK-4827: Functional PARP Sensitization Beyond BRCA

  2026-09-09

  MK-4827 (Niraparib) is a selective PARP-1/-2 inhibitor for dissecting DNA repair dependence in cancer research. This article develops a functional assay framework showing how BRCA2 protein state, hyperthermia, and orthogonal readouts can reveal PARP inhibitor sensitivity beyond fixed BRCA genotype.

• Baicalin Methyl Ester and Intestinal Barrier Repair

  2026-09-08

  A 2024 Biomedicine & Pharmacotherapy study shows that baicalin methyl ester attenuates LPS-induced intestinal barrier injury in mice and MODE-K epithelial cells. Its central contribution is the integration of P65 binding evidence with TNF-α, MLCK, and tight-junction measurements, linking inflammatory signaling to barrier restoration.

• hiPSC Intestinal Organoids for Pharmacokinetics

  2026-09-08

  The 2025 study establishes a more accessible route for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. Its differentiated monolayers contain intestinal epithelial cell types, including enterocytes with cytochrome P450 and transporter activities, making the platform relevant to human pharmacokinetic studies while still requiring enzyme-specific validation.

• Carbapenemase Gene Transmission in CREC

  2026-09-07

  A 2025 BMC Microbiology study mapped carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals, combining gene localization, conjugation, mobile-element analysis, and strain typing. Its findings show that blaNDM-1 was frequently plasmid-associated and readily transferable in vitro, highlighting the need to interpret resistance surveillance through both clonal and horizontal-transmission frameworks.

• Cefoperazone Sodium Salt: Research Workflows

  2026-09-07

  Cefoperazone sodium salt supports reproducible susceptibility testing, β-lactamase-resistance studies, and PK-informed biliary tract infection research. This guide translates comparative microbiology into practical formulation, assay-design, and troubleshooting decisions.

• Metabolomics Reveals Carbapenemase Resistance

  2026-09-05

  The reference study shows that LC-MS/MS metabolomics can distinguish carbapenemase-producing Enterobacterales from non-CPE isolates using a 21-metabolite biomarker panel. Its antibiotic-free workflow links resistant phenotypes to altered metabolic pathways and provides a foundation for faster, mechanism-informed diagnostics in antibiotic resistance studies.

• EphA2 Synthetic Lethality in MYC-Driven TNBC

  2026-09-04

  Ye and colleagues used a chemogenetic screen of approximately 600 kinase inhibitors to identify EphA2 inhibition as a selective vulnerability in MYC-driven triple-negative breast cancer. The lead compound ALW-II-41-27 induced intrinsic apoptosis in MYC-activated models, including p53-deficient contexts, and reduced tumor growth in two TNBC xenograft models without apparent toxicity.

• Piroxicam and Deracoxib in Canine Mammary Cancer Cells

  2026-09-04

  The reference study shows that piroxicam and deracoxib reduce viability and increase apoptosis in the CMT-U27 canine mammary carcinoma cell line, with combined treatment producing stronger effects at lower concentrations. Its value is primarily methodological and hypothesis-generating: MTT viability testing combined with flow-cytometric apoptosis and cell-cycle analysis provides a structured way to evaluate NSAID combinations without treating in vitro cytotoxicity as clinical efficacy.

• Sodium Overload and Mitochondrial Failure in NECSO

  2026-09-03

  The reference study identifies mitochondrial energy failure as the central mechanism linking TRPM4-mediated sodium influx to necrosis by sodium overload. Its findings connect mitochondrial Na+ and Ca2+ imbalance with impaired oxidative phosphorylation, ATP depletion, Na/K-ATPase failure, cell swelling, and lysis, providing a framework for interpreting sodium-driven cell injury assays.

• MAPK10–KRT16 Signaling in NSCLC Metastasis

  2026-09-03

  The reference study identifies MAPK10 as a metastasis-suppressing kinase that phosphorylates KRT16 at Ser356 and Ser397, enabling RNF213-dependent ubiquitination and proteasomal degradation. Cellular, animal, and clinical data support the MAPK10/KRT16/RNF213 axis as a mechanistic model and a candidate prognostic pathway in non-small cell lung cancer.

7954 records 1/531 page Next 12345 下5页 Last page